Rizonib
Product Code: 0
Pack Size: 60's
- Price: $410 ৳45000 ,
Each capsule contains Crizotinib INN 250 mg.
ALK-Positive Metastatic NSCLC: Rizonib is indicated for the treatment of patients with metastatic Non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ROS1-Positive Metastatic NSCLC: Rizonib is indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive.
Major Ingredients
Each capsule contains Crizotinib INN 250 mg.
Major Functionality
ALK-Positive Metastatic NSCLC: Rizonib is indicated for the treatment of patients with metastatic Non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ROS1-Positive Metastatic NSCLC: Rizonib is indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive.
Manufacture Information
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.
